Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

C. Eng, T.W. Kim, J. Bendell, G. Argilés, N.C. Tebbutt, M. Di Bartolomeo, A. Falcone, M. Fakih, M. Kozloff, N.H. Segal, A. Sobrero, Y. Yan, I. Chang, A. Uyei, L. Roberts, F. Ciardiello, J.B. Ahn, J. Asselah, S. Badarinath, S. BaijalS. Begbie, S. Berry, J.L. Canon, R.G. Carbone, A. Cervantes, Y.J. Cha, K. Chang, A. Chaudhry, E. Chmielowska, S.H. Cho, D. Chu, F. Couture, J. Cultrera, D. Cunningham, E. Van Cutsem, P.J. Cuyle, J. Davies, S. Dowden, M. Dvorkin, V. Ganju, R.V. Garcia, R. Kerr, T.Y. Kim, K. King, J. Kortmansky, K.O. Lam, J. Lee, A.S. Lee, B. Lesperance, E. Maiello

Research output: Contribution to journalArticle

Cite this

Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., Sobrero, A., Yan, Y., Chang, I., Uyei, A., Roberts, L., Ciardiello, F., Ahn, J. B., Asselah, J., Badarinath, S., ... Maiello, E. (2019). Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology, 20(6), 849-861. https://doi.org/10.1016/S1470-2045(19)30027-0